Table 3.
Univariate analyses of baseline characteristics for overall survival.
| Variable | HR (95% CI) | P value |
|---|---|---|
| Age, per 1 year increase | 0.99 (0.98–1.00) | 0.197 |
| Gender (ref: female) | 0.83 (0.57–1.22) | 0.349 |
| Etiology HBV/others (ref: HBV) | 0.84 (0.57–1.25) | 0.392 |
| Child-pugh A/B (ref: B) | 1.53 (0.78–2.99) | 0.216 |
| ECOG 0/≥1 (ref: score of 0) | 2.54 (1.90–3.39) | <0.001 |
| Previous treatments (ref: no) | 0.89 (0.55–1.44) | 0.628 |
| Tumor size, per 1 cm increase | 1.11 (1.07–1.15) | <0.001 |
| No. of HCC nodules, per 1 lesion increase | 1.14 (1.06–1.22) | <0.001 |
| PVTT (ref: absent) | 2.98 (2.18–4.07) | <0.001 |
| EHS (ref: absent) | 2.02 (1.48–2.75) | <0.001 |
| Ascites (ref: absent) | 1.95 (1.22–3.11) | 0.005 |
| AFP (ref: ≤400 ng/ml) | 1.82 (1.37–2.41) | <0.001 |
| Albumin, per 1 g/L increase | 0.96 (0.93–0.99) | 0.005 |
| Total bilirubin, per 1 μmol/L increase | 1.03 (1.02–1.05) | <0.001 |
| ALT, per 1 U/L increase | 1.00 (1.00–1.01) | 0.832 |
| AST, per 1 U/L increase | 1.01 (1.00–1.01) | <0.001 |
| INR, per 1% increase | 1.00 (0.99–1.01) | 0.600 |
Abbreviations: HR, hazard ratio; CI, confidence interval; HBV, hepatitis B virus; ECOG, Eastern Cooperative Oncology Group; HCC, hepatocellular carcinoma; PVTT, portal vein tumor thrombus; EHS, extrahepatic spreading; AFP, alpha-fetoprotein; ALT, Alanine aminotransferase; AST, Aspartate aminotransferase. INR, International normalized ratio.